References
- Diasio RB. An evolving role for oral fluoropyrimidine drugs. J Clin Oncol 2002; 20: 894–896.
- Schuller J, Cassidy J, Dumont E, et al. Preferential activation of capecitabine in tumor following oral administration in colorectal cancer patients. Cancer Chemother Pharmacol 2000; 45: 291–297.
- Miwa M, Ura M, Nishida M, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998; 34: 1274–1281.
- Twelves C. Vision of the future: Capecitabine. Oncologist 2001; 6 (Suppl 4): 35–39.
- Cassidy J, Twelves C, Van Cutsem E, et al. First-line oral capecitabine therapy in metastatic colorectal cancer: A favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 2002; 13: 566–575.
- Fumoleau P, Largillier R, Trillet-Lenoir V, et al. Capecitabine (Xeloda) in patients with advanced breast cancer (ABC), previously treated with anthracyclines and taxanes: a large Phase II study. Proc Am Soc Clin Oncol 2002; 21:62
- O’Shaughnessy J, Blum J, Moiseyenko V, et al. Randomized, open label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol 2001; 12: 1247–1254.
- O’Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol 2002; 20: 2812–2823.
- Blum JL, Dieras V, Lo Russo PM et al. Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 2001; 92: 1759–1768.
- Taguchi T, Nakayama T, Masuda N, Yoshidome K, et al. Study of low-dose capecitabine monotherapy for metastatic breast cancer. Chemotherapy 2010; 56(2):166–170.
- Ambros T, Zeichner SB, Zaravinos J, Montero AJ, Ahn E, Aruna M, et al. A retrospective study evaluating a fixed low dose capecitabine monotherapy in women with HER-2 negative metastatic breast cancer. Breast Cancer Res Treat 2014;146(1):7–14.
- Bertelsen C, Ji L, Garcia A, Russell C, et al. Efficacy of Very-Low-Dose Capecitabine in Metastatic breast Cancer. Am J Hematol 2014; 11(2):20–30
- Nishijima T, Suzuki M, Hyman B. A comparison of toxicity profiles between the lower and standard dose capecitabine in breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat 2016 April ; 156(2): 227–236.
- Rudek M, Connolly R, Hoskins J, Mayer E, et al. Fixed dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast cancer. Breast Cancer Res Treat 2013 May; 139(1): 135–143.
- Koedoot CG, De Haes JC, Heisterkamp SH, Bakker PJ, et al. Palliative chemotherapy or watchful waiting? A vignettes study among oncologists. J Clin Oncol 2002;20(17):3658–3664.
- Rossi D, Alessandroni P, Catalano V et al. Safety profile and activity of lower capecitabine dose in patients with metastatic breast cancer. Clin Breast Cancer 2007; 7(11): 857–860.
- Kawaguchi T, Iwase S, Takeuchi H, et al. Chemotherapy with low-dose capecitabine as palliative treatment in a patient with metastatic breast cancer: a case report. Cases J 2009;2:9081.
- Blum JL, Jones SE, Buzdar AU, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999; 17(2): 485–493.
- Van Cutsem E, Findlay M, Osterwalder B, et al. Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. J Clin Oncol 2000; 18(6): 1337–1345.
- Haller DG, Cassidy J, Clarke SJ, et al. Potential regional differences for the tolerability profiles of fluoropyrimidines. J Clin Oncol 2008; 26(13): 2118–2123.
- Sezgin C, Kurt E, Evrensel T et al. Efficacy of lower dose capecitabine in patients with metastatic breast cancer and factors influencing therapeutic response and outcome. South Med J 2007; 100(1): 27–32.
- Hennessy B, Gauthier A, Michaud L, Hortobagyi G, et al Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review of capecitabine toxicity in the literature. Ann Oncol 2005; 16: 1289–1296.
- Cassidy J, Twelves C, Van Cutsem E, et al. First-line oral capecitabine therapy in metastatic colorectal cancer: A favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 2002; 13: 566–575.
- Zielinski C, Gralow J, Martin M. Optimizing the dose of capecitabine in metastatic breast cancer: confused, clarified or confirmed? Ann Oncol 2010; 21: 2145–2152.
- Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine (Xeloda) v intravenous 5-fluorouracil plus leucovorin (Mayo Clinic regimen) as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study. J Clin Oncol 2001; 19: 2282–2292.
- Talbot DC, Moiseyenko V, Van Belle S, et al. Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Br J Cancer 2002; 86: 1367–1372.
- Harbeck N, Saupe S, Jäger E, Schmidt M, et al. A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: Results of the PELICAN study. Breast Cancer Res Treat 2017;161(1):63–72.
- Robert NJ, Dieras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011; 29(10):1252–1260.
- Stockler MR, Harvey VJ, Francis PA, Byrne MJ, Ackland SP, Fitzharris B, et al. Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer. J Clin Oncol 2011; 29(34):4498–4504.
- Debled M, Madranges N, Trainaud A, et al. First-line capecitabine monotherapy for slowly progressing metastatic breast cancer: do we need aggressive treatment? Oncology 2009; 77: 318–327.
- Bajetta E, Procopio G, Celio L, et al. Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J Clin Oncol 2005; 23(10): 2155–2161.